Multiple sclerosis: following clues from cause to cure

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 6-8

  MacLean, Heather J ^a   Freedman, Mark S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; INTERMEDIN; MITOXANTRONE; NATALIZUMAB; VITAMIN D;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 57249092711     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70272-2     Document Type: Note

References (10)

1. Kragt J.J., van Amerongen B.M., Killestein J., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler (2008) 10.1177/1352458508095920 published online August 13.
2. Dwyer T., van der Mei I., Ponsonby A.-L., et al. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology 71 (2008) 583-589
3. Mikol D.D., Barkhof F., Chang P., et al., on behalf of the REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study: a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7 (2008) 903-914
4. Oger J., Francis G., Chang P., and PRISMS Study Group. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study. J Neurol Sci 237 (2005) 45-52
5. The CAMMS223 study investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med 359 (2008) 1786-1801
6. Polman C.H., O'Connor P.W., Havrdova E., et al., AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
7. O'Connor P., Arnason B., Comi G., et al. Interferon beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose study. Abstract LBS-004. http://www.aan.com/globals/axon/assets/4088.pdf (accessed November 25, 2008).
8. Krishnan C., Kaplin A.I., Brodsky R.A., et al. Reduction of diseae activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 65 (2008) 1044-1051
9. Fagius J., Lundgren J., and Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler (2008) 10.1177/1352458508096875 published online September 19.
10. Chang A., Smith M.C., Yin X., Fox R.J., Staugaitis S.M., and Trapp B.D. Neurogenesis in the chronic lesions of multiple sclerosis. Brain 131 (2008) 2366-2375